Effectiveness of BNT162b2 Vaccine Against Omicron-SARS-CoV-2 Subvariants in Children 5-11 Years of Age in Quebec, Canada, January 2022 to January 2023.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
medline:
3
11
2023
pubmed:
3
11
2023
entrez:
3
11
2023
Statut:
aheadofprint
Résumé
In premarketing clinical trials conducted before Omicron emergence, BNT162b2 vaccine efficacy against COVID-19 was 90% in children. We conducted postmarketing evaluation of 1- and 2-dose vaccine effectiveness (VE) against Omicron BA.1, BA.2 and BA.4/5 subvariants in 5- to 11-year olds. We estimated VE against SARS-CoV-2 infection using a test-negative design. Specimens collected between January 9, 2022, and January 7, 2023, from children 5-11 years old in Quebec, Canada, and tested by nucleic acid amplification test were eligible. We estimated VE by time since last vaccine dose, interval between doses and by period of Omicron subvariant predominance. A total of 48,826 NAATs were included in overall analysis. From 14-55 to 56-385 days postvaccination, 2-dose VE against symptomatic infection decreased from 68% (95% CI, 62-74) to 25% (95% CI, 11-36). Two-dose VE with restriction to specimens collected from acute care hospitals (emergency rooms or wards) did not decline but was stable at ~40%. VE against symptomatic infection remained comparable at any interval between doses but increased with longer interval among children tested in acute care settings, from 18% (95% CI, -17 to 44) with 21- to 55-day interval to 69% (95% CI, 43-86) with ≥84-day interval. Two-dose VE against symptomatic infection dropped from 70% (95% CI, 63-76) during BA.1, to 32% (95% CI, 13-47) with BA.2 and to nonprotective during BA.4/5 dominance. In children 5-11 years of age, VE against symptomatic infection was stable at any interval between doses but decreased with time since the last dose and against more divergent omicron subvariants.
Sections du résumé
BACKGROUND
BACKGROUND
In premarketing clinical trials conducted before Omicron emergence, BNT162b2 vaccine efficacy against COVID-19 was 90% in children. We conducted postmarketing evaluation of 1- and 2-dose vaccine effectiveness (VE) against Omicron BA.1, BA.2 and BA.4/5 subvariants in 5- to 11-year olds.
METHODS
METHODS
We estimated VE against SARS-CoV-2 infection using a test-negative design. Specimens collected between January 9, 2022, and January 7, 2023, from children 5-11 years old in Quebec, Canada, and tested by nucleic acid amplification test were eligible. We estimated VE by time since last vaccine dose, interval between doses and by period of Omicron subvariant predominance.
RESULTS
RESULTS
A total of 48,826 NAATs were included in overall analysis. From 14-55 to 56-385 days postvaccination, 2-dose VE against symptomatic infection decreased from 68% (95% CI, 62-74) to 25% (95% CI, 11-36). Two-dose VE with restriction to specimens collected from acute care hospitals (emergency rooms or wards) did not decline but was stable at ~40%. VE against symptomatic infection remained comparable at any interval between doses but increased with longer interval among children tested in acute care settings, from 18% (95% CI, -17 to 44) with 21- to 55-day interval to 69% (95% CI, 43-86) with ≥84-day interval. Two-dose VE against symptomatic infection dropped from 70% (95% CI, 63-76) during BA.1, to 32% (95% CI, 13-47) with BA.2 and to nonprotective during BA.4/5 dominance.
CONCLUSIONS
CONCLUSIONS
In children 5-11 years of age, VE against symptomatic infection was stable at any interval between doses but decreased with time since the last dose and against more divergent omicron subvariants.
Identifiants
pubmed: 37922479
doi: 10.1097/INF.0000000000004145
pii: 00006454-990000000-00624
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Canada H. Health Canada authorizes use of Comirnaty (the Pfizer-BioNTech COVID-19 vaccine) in children 5 to 11 years of age. Published November 19, 2021. Available at: https://www.canada.ca/en/health-canada/news/2021/11/health-canada-authorizes-use-of-comirnaty-the-pfizer-biontech-covid-19-vaccine-in-children-5-to-11-years-of-age.html. Accessed September 29, 2022.
Walter EB, Talaat KR, Sabharwal C, et al.; C4591007 Clinical Trial Group. Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age. N Engl J Med. 2022;386:35–46.
Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5–11 years and adolescents aged 12–15 years — PROTECT cohort, July 2021–February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:422–428.
Price AM, Olson SM, Newhams MM, et al.; Overcoming Covid-19 Investigators. BNT162b2 protection against the omicron variant in children and adolescents. N Engl J Med. 2022;386:1899–1909.
Fleming-Dutra KE, Britton A, Shang N, et al. Association of Prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during omicron predominance. JAMA. 2022;327:2210–2219.
Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19–associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5–17 years — VISION network, 10 States, April 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71:352–358.
Simmons AE, Amoako A, Grima AA, et al. Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: a retrospective cohort study. Plos One. 2023;18:e0283715.
Sacco C, Manso MD, Mateo-Urdiales A, et al. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022. Lancet. 2022;400:97–103.
Cohen-Stavi CJ, Magen O, Barda N, et al. BNT162b2 vaccine effectiveness against Omicron in children 5 to 11 years of age. N Engl J Med. 2022;387:227–236.
Tan SHX, Cook AR, Heng D, et al. Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age. N Engl J Med. 2022;387:525–532.
Lau YL, Leung Daniel, Duque Jaime Rosa, Yip Ka Man, So Hung Kwan, Wong Wilfred. Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong. doi:10.21203/rs.3.rs-1856540/v1
Chemaitelly H, AlMukdad S, Ayoub H, et al. Covid-19 vaccine protection among children and adolescents in Qatar. N Engl J Med. 2022;387:1865–1876.
Piché-Renaud PP, Swayze S, Buchan S, Wilson Sarah, Austin Peter C., Morris Shaun K., Nasreen Sharifa, Schwartz Kevin L., Tadrous Mina, Thampi Nisha, Wilson Kumanan, Kwong Jeffrey C., Group Canadian Immunization Research Netw. Vaccine effectiveness of BNT162b2 against omicron in children aged 5-11 years: a test-negative design. Published online August 1, 2022. doi:10.2139/ssrn.4176388
Cocchio S, Zabeo F, Tremolada G, et al. COVID-19 vaccine effectiveness against omicron variant among underage subjects: the Veneto region’s experience. Vaccines. 2022;10:1362.
Lin DY, Gu Y, Xu Y, et al. Effects of vaccination and previous infection on omicron infections in children. N Engl J Med. 2022;387:1141–1143.
Duque JSR, Leung D, Yip KM, et al. Effectiveness of BNT162b2 and CoronaVac against pediatric COVID-19-associated hospitalization and moderate-to-severe disease. medRxiv. 2022: 2022.09.09.22279426. Available at: https://www.medrxiv.org/content/10.1101/2022.09.09.22279426v1. [cited 2022 Sep 12].
Khan FL, Nguyen JL, Singh TG, et al. Estimated BNT162b2 vaccine effectiveness against infection with delta and omicron variants among US children 5 to 11 years of age. JAMA Netw Open. 2022;5:e2246915.
Dorabawila V, Hoefer D, Bauer UE, et al. Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the emergence of the omicron variant. medRxiv. 2022:2022.02.25.22271454. Available at: https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1. [cited 2023 Oct 9].
Ionescu IG, Skowronski DM, Sauvageau C, et al. BNT162b2 effectiveness against delta and omicron variants of severe acute respiratory syndrome coronavirus 2 in adolescents aged 12–17 years, by dosing interval and duration. J Infect Dis. 2023;227:1073–1083.
Skowronski DM, Febriani Y, Ouakki M, et al. Two-dose severe acute respiratory syndrome coronavirus 2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Clin Infect Dis. 2022;75:1980–1992.
Canada PHA of. Archived 24: National Advisory Committee on Immunization (NACI) statement: Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [2021-11-19]. Published November 23, 2021. Available at: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/pfizer-biontech-10-mcg-children-5-11-years-age.html. Accessed March 17, 2022.
Vaccination contre la COVID-19 chez les jeunes âgés de 5 à 11 ans au Québec. INSPQ. Available at: https://www.inspq.qc.ca/publications/3181-vaccination-covid19-jeunes-5-11-ans. Accessed July 25, 2022.
Archives des données COVID-19. INSPQ. Available at: https://www.inspq.qc.ca/covid-19/donnees/archives. Accessed August 29, 2022.
Le variant Omicron est désormais dominant au Québec. INSPQ. Available at: https://www.inspq.qc.ca/nouvelles/variant-omicron-est-desormais-dominant-quebec. Accessed August 29, 2022.
Données sur les variants du SRAS-CoV-2 au Québec. INSPQ. Available at: https://www.inspq.qc.ca/covid-19/donnees/variants. Accessed August 29, 2022.
Calendrier et salle de presse du CHU Sainte-Justine. Available at: https://www.chusj.org/en/Calendrier-salle-presse/nouvelles/actualites/2022/Combien-d-enfants-sont-proteges-contre-la-COVID-19. Accessed June 29, 2022.
Calendrier et salle de presse du CHU Sainte-Justine. Available at: https://www.chusj.org/fr/Calendrier-Salle-de-presse/Salle-de-presse/Actualites-/2022/Combien-d-enfants-sont-proteges-contre-la-COVID-fr. Accessed August 29, 2022.
Calendrier et salle de presse du CHU Sainte-Justine. Available at: https://www.chusj.org/fr/Calendrier-Salle-de-presse/Salle-de-presse/Actualites-/2022/Combien-d-enfants-et-d-adultes-sont-proteges-contr. Accessed August 29, 2022.
Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671–675.
Arora P, Kempf A, Nehlmeier I, et al. Augmented neutralisation resistance of emerging omicron subvariants BA2121, BA4, and BA5. Lancet Infect Dis. 2022;22:1117–1118.
Wilhelm A, Widera M, Grikscheit K, et al. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA1 and BA2 by convalescent and vaccine serum and monoclonal antibodies. eBioMedicine. 2022;82:104158.
Planas D, Staropoli I, Porot F, et al. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. Med. 2022;3:838–847.e3.
Barouch DH. Covid-19 Vaccines — Immunity, Variants, Boosters. N Engl J Med. 2022;387:1011–1020.
Hachmann NP, Miller J, ris Y CA, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA2121, BA4, and BA5. N Engl J Med. 2022;387:86–88.
Cao Y, Yisimayi A, Jian F, et al. BA2121, BA4 and BA5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593–602.
Khan K, Karim F, Ganga Y, et al.; COMMIT-KZN Team. Omicron BA4/BA5 escape neutralizing immunity elicited by BA1 infection. Nat Commun. 2022;13:4686.
Carazo S, Skowronski DM, Brisson M, et al. Effectiveness of previous infection-induced and vaccine-induced protection against hospitalisation due to omicron BA subvariants in older adults: a test-negative, case-control study in Quebec, Canada. Lancet Healthy Longev. 2023;4:e409–e420.
Administration d’une dose de vaccin bivalent aux p.pdf. Available at: https://www.inspq.qc.ca/sites/default/files/publications/3268-administration-vaccin-bivalent-vaccin-monovalent-covid-19.pdf. Accessed January 13, 2023.